HOME >> BIOLOGY >> NEWS
Vion Demonstrates Readiness Of First Tumor-Targeting Salmonella For Human Testing Against Solid Tumors

Stability, Safety and Efficacy Demonstrated for Novel Bacterial Anticancer Agent

NEW HAVEN, CT (April 12, 1999): Research by scientists at Vion Pharmaceuticals (Nasdaq: VION) and their Yale University collaborators demonstrates the suitability of the company's lead TAPETR vector, VNP20009, to enter human clinical testing. At the annual meeting of the American Association of Cancer Research (AACR) Vion scientists presented data demonstrating the genetically engineered Salmonella bacteria's overall safety profile and tumor targeting ability, including TAPET's safety when administered to non-human primates. In addition, they reported the ability of unarmed TAPET organisms (without "warheads") to inhibit both primary and metastatic tumors by more than 90% and to prolong survival in mouse xenograft models (human tumor tissue transplanted into mice) of several human cancers. In March, Vion announced that the company had filed an Investigational New Drug (IND) application to begin human safety testing with TAPET in the United States later this year. The U.S. filing is in addition to regulatory filings made by Vion in support of clinical trials of TAPET in Europe. Vion is developing TAPET organisms as vectors for the targeted, systemic delivery of anticancer agents to tumors throughout the body.

David Bermudes, Ph.D., associate director of biology at Vion, said, "VNP20009 possesses all of the properties required for its safe use in humans. These include attenuated virulence, a reduction in the potential of the bacterium to elicit septic shock, genetic stability in its safety-related mutations, and sensitivity to conventional antibiotics. At the same time, VNP20009 maintains TAPET's desirable anti-tumor properties, including the ability to selectively amplify in tumors at levels of at least 500:1 compared with normal tissues and to suppress tumor growth by more than 90%. Moreover, the VNP20009 TAPET strain is easily amenable
'"/>

Contact: Joan Kureczka
jkureczka@aol.com
415-821-2413
Kureczka/Martin Associates
11-Apr-1999


Page: 1 2 3

Related biology news :

1. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
2. Engineering Animation, Inc. Demonstrates Internet Anatomy At Visible Human Project Conference
3. Study Demonstrates High Conservation Potential Of Logged Rainforest
4. First glimpse of DNA binding to viral enzyme
5. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
6. 2nd media alert First Scientific Conference on Childhood Leukaemia
7. First International Scientific Conference on Childhood Leukaemia
8. First ever standards linking climate change, biodiversity and poverty seek global peer review
9. First genetic comparison of purebred domestic dogs produces surprises
10. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
11. First target for childhood malaria vaccine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... the prestigious international IAIR Award for the most innovative high security ePassport ... ... Maldives Immigration Controller General, Mr. ... on the right) have received the IAIR award for the "Most innovative ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition ... Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the ... a CAGR of 29.63% between 2017 and 2022. ... ... ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... , ... April 20, 2017 , ... NetDimensions appoints Bill ... , With over 20 years of experience in the learning technologies industry, Mastin joins ... company within Learning Technologies Group plc (LTG). At LEO, Mastin served as SVP of ...
(Date:4/20/2017)... ... April 20, 2017 , ... Open Therapeutics ... property (IP) sharing and commercialization model. , The Center for Advancing Innovation helps ... of this effort is bringing the IP to the attention of the entrepreneurial ...
(Date:4/19/2017)... (PRWEB) , ... April 18, 2017 , ... ... 1970s and has been a key device for generating monodisperse droplets of known ... droplet processes and for generating monodisperse solid particles by drying monodisperse droplets. ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics Announces ... Seeks to Leverage Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial , ... 81 patient clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the ...
Breaking Biology Technology:
Cached News: